RevcoviAdenosine deaminase deficiency - severe combined immune deficiency (ADA-SCID) in adults and children
New molecular entity
Development and Regulatory status
Jan 22Communication from Chiesi states - Revcovi does not have a marketing authorisation in the UK, and there are no plan for the future 
Nov 20Chiesi Global Rare Diseases announces that Chiesi Group has acquired Unikeris Limited,global marketer for Revcovi for the treatment of adenosine deaminase deficiency severe combined immunedeficiency (ADA-SCID), which was approved in the US in October 2018 and is available to patients in the EU through a named-patient access programme 
Feb 20Launched in US .
Oct 18Approved in US for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in paediatric and adult patients .
PEGylated recombinant adenosine deaminase (rADA) enzyme therapy
ADA deficiency is very rare and is estimated to occur in approximately 1 in 200,000 to 1,000,000 newborns worldwide. Most individuals are diagnosed in the first 6 months of life. Without treatment, they do not usually survive past age 2 years. In 10 to 15% of cases, onset of immune deficiency occurs between 6 and 24 months of age (delayed onset) or in adulthood (late onset) .
Adenosine deaminase deficiency - severe combined immune deficiency (ADA-SCID) in adults and children